^
Association details:
| Biomarker: | EGFR exon 19 deletion + ALK mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations
Published date:
10/15/2021
Excerpt:
Patients with concurrent EGFR and ALK mutations were included in this study, which analyzed mutation profiles and treatment histories....Kaplan-Meier analysis showed that after the first line of EGFR-TKI treatment, the median PFS (mPFS) of patients with EGFR 19del/ALK co-mutation (n = 4) was significantly higher than that of patients with non-EGFR19del/ ALK co-mutation (n = 4, one patient had unclear PFS information, mPFS of 21.5 vs 7.25 months, p = 0.007...
DOI:
https://doi.org/10.1186/s12885-021-08824-2
